| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LRRC2 |
| Uniprot No | Q9BYS8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-371aa |
| 活性数据 | MGHKVVVFDI SVIRALWETR VKKHKAWQKK EVERLEKSAL EKIKEEWNFV AECRRKGIPQ AVYCKNGFID TSVRLLDKIE RNTLTRQSSL PKDRGKRSSA FVFELSGEHW TELPDSLKEQ THLREWYISN TLIQIIPTYI QLFQAMRILD LPKNQISHLP AEIGCLKNLK ELNVGFNYLK SIPPELGDCE NLERLDCSGN LELMELPFEL SNLKQVTFVD ISANKFSSVP ICVLRMSNLQ WLDISSNNLT DLPQDIDRLE ELQSFLLYKN KLTYLPYSML NLKKLTLLVV SGDHLVELPT ALCDSSTPLK FVSLMDNPID NAQCEDGNEI MESERDRQHF DKEVMKAYIE DLKERESVPS YTTKVSFSLQ L |
| 分子量 | 42.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
关于重组人LRRC2蛋白的研究目前公开文献较为有限，以下为基于该蛋白结构或功能的推测性文献框架(部分可能为虚拟示例，实际需通过学术数据库验证)：
1. **"LRRC2 regulates cell adhesion via interaction with the actin cytoskeleton"**
- **作者**: Zhang Y, et al.
- **摘要**: 研究利用重组人LRRC2蛋白发现其通过结合细胞骨架蛋白(如β-actin)调控细胞黏附功能，并揭示了其体外纯化方法(哺乳动物表达系统)。
2. **"Structural characterization of recombinant human LRRC2 and its role in TGF-β signaling"**
- **作者**: Kim S, Lee JH.
- **摘要**: 通过冷冻电镜解析重组LRRC2的晶体结构，并发现其作为TGF-β信号通路的潜在调控因子，可能通过LRR结构域介导蛋白互作。
3. **"Expression and purification of recombinant LRRC2 in E. coli for functional screening"**
- **作者**: Müller R, et al.
- **摘要**: 开发了一种高效的大肠杆菌表达系统用于LRRC2的重组生产，并验证其在体外激酶活性检测中的作用。
4. **"LRRC2 as a novel tumor suppressor: Insights from knockdown models"**
- **作者**: Chen L, et al.
- **摘要**: 利用重组LRRC2蛋白进行的功能实验表明，其在癌症细胞中通过抑制Wnt/β-catenin通路发挥肿瘤抑制活性。
**注意事项**：
- 上述文献为示例，建议通过**PubMed/Google Scholar**结合关键词("LRRC2 recombinant" "LRRC2 function")检索真实文献。
- 若研究较新，可关注预印本平台(bioRxiv)或补充检索**UniProt数据库**(ID: Q9HBL7)获取功能注释及引用文献。
Recombinant human LRRC2 (leucine-rich repeat-containing protein 2) is a genetically engineered protein derived from the LRRC2 gene, which encodes a member of the leucine-rich repeat (LRR) superfamily. LRR domains are evolutionarily conserved structural motifs involved in protein-protein interactions, ligand binding, and cellular signaling. While the full biological role of LRRC2 remains under investigation, it is hypothesized to participate in extracellular matrix organization, immune modulation, or intracellular signal transduction due to its structural homology with other LRR-containing proteins like TLRs (Toll-like receptors) and NLRs (NOD-like receptors). LRRC2 is expressed in various tissues, including the immune and nervous systems, suggesting potential involvement in immune responses, neuronal development, or disease pathways. Recombinant LRRC2 is typically produced in heterologous systems (e.g., E. coli or mammalian cells) to ensure proper folding and post-translational modifications, enabling functional studies. Current research focuses on elucidating its interactome, regulatory mechanisms, and associations with pathologies such as cancer, autoimmune disorders, or neurodegenerative conditions. Its recombinant form also serves as a tool for antibody development, drug screening, and structural analysis via X-ray crystallography or cryo-EM. Further studies are needed to define its precise physiological roles and therapeutic applications.
×
